Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 5, keine Gesamtzahl für „serious“
Suchtreffer
Begriffe & Kennungen
Amsparity · 4.8 · In controlled and open-label adult and paediatric studies with adalimumab, serious infections (including fatal
Eintrag öffnenAmsparity · 4.8 · In controlled and open-label adult and paediatric studies with adalimumab, serious infections (including fatal
Eintrag öffnenAmsparity · 4.8 · In controlled and open-label adult and paediatric studies with adalimumab, serious infections (including fatal
Eintrag öffnenAmsparity · 4.8 · Serious adverse reactions have been reported for adalimumab. TNF-antagonists, such as adalimumab affect the im
Eintrag öffnenAmsparity · 4.8 · Serious adverse reactions have been reported for adalimumab. TNF-antagonists, such as adalimumab affect the im
Eintrag öffnenAmsparity · 4.8 · Serious adverse reactions have been reported for adalimumab. TNF-antagonists, such as adalimumab affect the im
Eintrag öffnenAmsparity · 4.8 · Serious haematological, neurological and autoimmune reactions have also been reported. These include rare repo
Eintrag öffnenAmsparity · 4.8 · Serious haematological, neurological and autoimmune reactions have also been reported. These include rare repo
Eintrag öffnenAmsparity · 4.8 · The incidence of serious infections was 0.04 per patient year in adalimumab-treated patients and 0.03 per pati
Eintrag öffnenAmsparity · 4.8 · The incidence of serious infections was 0.04 per patient year in adalimumab-treated patients and 0.03 per pati
Eintrag öffnenAmsparity · 4.8 · The incidence of serious infections was 0.04 per patient year in adalimumab-treated patients and 0.03 per pati
Eintrag öffnenAmversio · 4.8 · In general, adverse reactions seen with betaine anhydrous therapy appeared to be not serious and are mainly re
Eintrag öffnenApexelsin · 4.8 · 17 frequently reported adverse reactions were neutropenia, anaemia, leukopenia and pyrexia. Serious adverse re
Eintrag öffnenApidra · 4.8 · Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. MedDRA Ver
Eintrag öffnenArava · 4.3 · • Patients with serious infections (see section 4.4).
Eintrag öffnenArava · 4.3 · • Patients with serious infections (see section 4.4).
Eintrag öffnenArava · 4.3 · • Patients with serious infections (see section 4.4).
Eintrag öffnenArava · 4.8 · Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Eintrag öffnenArava · 4.8 · Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Eintrag öffnenArava · 4.8 · Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Eintrag öffnen